Day: December 1, 2021

FREMONT, Calif., Dec. 01, 2021 (GLOBE NEWSWIRE) — Enovix Corporation (“Enovix”) (Nasdaq: ENVX, ENVXW), the leader in the design and manufacture of next-generation 3D Silicon™ Lithium-ion batteries, today announced that the management team will present at the Raymond James 2021 Technology Investors Conference on Monday, December 06, 2021 at 1:20 PM Eastern Time. A live webcast of the presentation can be accessed by selecting Events under the News and Events section of the Enovix website at https://ir.enovix.com. A replay of the webcast will be archived for one year following the presentation, also in the Events section. Management will also be available for one-on-one meetings with institutional investors at the conference. Portfolio managers and analysts who wish to request a meeting should contact your respective sales representative...

CENTREVILLE, Va., Dec. 01, 2021 (GLOBE NEWSWIRE) — Parsons Corporation (NYSE: PSN) announced today that the company was recognized with a Gold Award for Project Development by the Canadian Council for Public-Private Partnerships. The award honors outstanding achievements in public-private partnerships (P3s) for Parsons’ work as part of the Valley Line West Light Rail Train (LRT) team. The Valley Line West LRT contract, a $2.65 billion, 14-kilometer light rail extension project, was awarded in December 2020 and is currently being designed by joint venture partners Colas Canada and Parsons. The award recognizes the project development team for excellence and innovation in P3s which result in enhanced quality of public services and facilities. “We are a proud part of the Valley Line West LRT team, working to deliver a transformative...

60% of General Counsel Indicated Worry over Mounting Risks, Many Cited Lagging Preparedness in Critical Areas WASHINGTON, Dec. 01, 2021 (GLOBE NEWSWIRE) — FTI Consulting, Inc. (NYSE: FCN) today announced findings from its Technology segment’s annual study of corporate legal departments, in partnership with global legal and compliance technology company Relativity. Based on a detailed survey and one-on-one interviews between Ari Kaplan and chief legal officers at large corporations, The General Counsel Report 2022: Leading with Endurance Through Risk, Culture and Technology Challenges, revealed that emerging expectations and obstacles are demanding unprecedented resolve from corporate legal teams. In a series of three installments, the report will cover the key areas — across risk, culture and technology — that general counsel expect...

$29 billion secured capital program largely funded by cash from operations CALGARY, Alberta, Dec. 01, 2021 (GLOBE NEWSWIRE) — News Release — TC Energy Corporation (TSX, NYSE: TRP) (TC Energy) will host its annual Investor Day in a virtual format today. During the event we will provide an overview of our corporate strategy, five-year financial outlook and the targets we have set to support our ten sustainability commitments. In addition, we will outline the vast opportunity set that lies ahead for our natural gas pipelines, liquids pipelines and power and storage businesses in Canada, the United States and Mexico. “Our vision is to be the premier energy infrastructure company in North America, now and in the future,” said François Poirier, TC Energy’s President and Chief Executive Officer. “Our $100 billion portfolio of high-quality,...

1 December 2021 LONDON, Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the treatment of diseases with significant unmet medical need, today announced that Deep Track Capital, a U.S. investment firm focused exclusively on the life sciences industry, purchased approximately $22 million of American Depository Shares (ADSs) in Silence from existing shareholders. Gerard Smith, M.D., Principal at Deep Track Capital, said: “Silence has a promising wholly-owned clinical stage pipeline in addition to its proprietary mRNAi GOLD™ platform that we believe could drive long term growth and value creation for patients and shareholders. We look forward to supporting the Silence team in the journey ahead.” Mark Rothera,...

– Positive topline results validated by additional analyses – Patient improvements beyond reduction of depression symptoms – Further insights into timing and circumstance of adverse events demonstrate COMP360 psilocybin therapy was generally well-tolerated London, UK – 1 December 2021              COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced further results from its groundbreaking phase IIb clinical trial of COMP360 psilocybin therapy for treatment-resistant depression (TRD). Additional analyses of primary and secondary endpoints validated topline findings and provided more insights into safety data. Analyses of exploratory measures including anxiety, self-reported depression, positive...

Hamilton, Bermuda, Dec. 01, 2021 (GLOBE NEWSWIRE) — GasLog Ltd., (“GasLog” or “Company”) today announces that it has ordered four newbuild 174,000 cubic meter liquefied natural gas carriers with the latest generation MEGI propulsion from Daewoo Shipbuilding and Marine Engineering Co., Ltd. for delivery in 2024 and 2025. Contacts:  Joseph Nelson Head of Investor Relations Phone: +1 212-223-0643  Email: ir@gaslogltd.com  About GasLog  GasLog is an international owner, operator and manager of LNG carriers providing support to international energy companies as part of their LNG logistics chain. GasLog’s consolidated fleet consists of 39 LNG carriers (35 on the water plus 4 under construction). Of these vessels, 21 are owned by GasLog, three have been sold and leased back by GasLog under long-term bareboat charters and the remaining...

New Trial Designed to Further Investigate the Immune-Based MOA of Trilaciclib and Help Determine Future Target Tumor Types and Treatment Combinations RESEARCH TRIANGLE PARK, N.C., Dec. 01, 2021 (GLOBE NEWSWIRE) — G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that the Company has initiated a Phase 2, single arm, open-label study of trilaciclib in patients with early-stage triple negative breast cancer (TNBC) designed to further investigate the role of trilaciclib in modulating the anti-tumor immune response. Pathologic complete response endpoints are also being evaluated in this trial. Initial results of this study are expected in the second half of 2022. “Data from our Phase 2 TNBC trial of trilaciclib in combination with chemotherapy showed clinically meaningful and substantial improvements...